Recently, the Center for Drug Evaluation (CDE) of the State Drug Administration formally included AbbVie's clinically developed sterile lyophilized powder for infusion, Telisotuzumab Vedotin (Teliso-V), into the list of breakthrough therapeutic drug varieties for the treatment of advanced/late stage c-Met protein (OE) with high expression of c-Met protein (OE) with disease progression occurring during or after platinum-based drug therapy. metastatic epidermal growth factor receptor (EGFR) wild-type (WT) non-squamous (NSq) non-small cell lung cancer (NSCLC) patients.

About Telisotuzumab Vedotin (Teliso-V)

Teliso-V is an investigational first-in-class antibody-coupled drug (ADC) targeting the c-MET protein in patients with tumors overexpressing c-Met, a receptor tyrosine kinase that is overexpressed in many solid tumors, including NSCLC. Its efficacy safety as monotherapy in previously treated patients with c-Met overexpressing NSCLC will be further evaluated in the randomized Phase 3 study TeliMET NSCLC-01 (Study M18-868) For more information on the Teliso-V clinical trial, please visit https://clinicaltrials.gov/. Currently, there are no approved cancer therapies specifically targeting patients with c-Met overexpressing NSCLC. teliso-V has not received any regulatory approvals and its safety and efficacy have not been established.

About Non-Small Cell Lung Cancer

Lung cancer ranks first among all malignant tumors in China in terms of morbidity and mortality, with non-small cell lung cancer (NSCLC) accounting for about 85% of all lung cancers, and most of the patients are already in advanced stages at the time of diagnosis, which usually has a poor prognosis.

https://mp.weixin.qq.com/s?__biz=MzAxODMzODc2OA==&mid=2650198743&idx=1&sn=3fbfbc1020a0e2a93255e7d338f9a87f&chksm=83d5b468b4a23d7ed309f69e4fa0f5936410b18334a7b05f2b788dca93ac4f0a08f8400f318e&mpshare=1&scene=1&srcid=0612Tn27RfIXgERYt96YLyFu&sharer_shareinfo=aeedc0912e266ed5963e131ece26695b&sharer_shareinfo_first=aeedc0912e266ed5963e131ece26695b#rd